GLP-1 receptor agonists are now well established as weight-loss treatments, but until recently, they have been available exclusively as injections.

Lilly, headquartered in Indianapolis, announced that the oral GLP-1 receptor agonist orforglipron reduced the average body weight by 12.4% in a phase 3 trial.

The effect was comparable to that seen with injectable semaglutide, and German experts remain cautious about the findings.

“The results show that the oral GLP-1 receptor agonist orforglipron leads to a more than 10% reduction in body weight compared to placebo. This reduction is only slightly lower than that achieved with semaglutide, which must be injected weekly. There are also no significant differences in side effects,” said Stephan Martin, MD, chief physician for diabetology and

See Full Page